Abpro Holdings, Inc. (ABPO) stock
Close on Oct 19, 2026Market cap $2.41MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.41M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- EPS, diluted
- -$1.30
- Book value per share
- -$0.60
- Diluted shares
- 6M
Trading
- Previous close
- $0.41
- Open
- $0.36
- Day's range
- $0.36 – $0.41
- Volume
- 548
- Average volume (20 days)
- 5,990
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ABPO | S&P 500 | Difference | ABPO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.6% | +0.6% | +4.0 pts | ||
| 3 months | +87.0% | +3.4% | +83.7 pts | ||
| Year to date | -90.4% | +13.3% | −103.6 pts | ||
| 1 year | -92.8% | +16.6% | −109.5 pts | ||
| 3 years | -99.9% | +86.4% | −186.2 pts | -89.1% | +23.1% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Abpro filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Abpro
Biological Products, (No Diagnostic Substances)
Abpro Holdings, Inc. is a biotechnology company focused on developing next-generation antibody therapeutics for patients with severe and life-threatening conditions. The company utilizes its proprietary antibody discovery and engineering platforms, DiversImmune and MultiMab, to design multi-specific antibody candidates primarily targeting immuno-oncology, ophthalmology, and infectious diseases. Its core pipeline includes ABP-102, a bispecific T-cell engager targeting HER2 and CD3 for solid tumors such as breast and gastric cancers, and ABP-201, a bispecific candidate designed to inhibit VEGF and ANG-2 to treat vascular diseases of the eye like wet age-related macular degeneration. The company pursues collaborative agreements and licensing partnerships with third-party biopharmaceutical developers, including Celltrion and Abpro Bio, to advance its programs.
Company profile, executives and historyAbpro stock: common questions
What is Abpro's stock price?
ABPO closed at $0.41 on Oct 19, 2026, up 0.11% on the day.
What is Abpro's market cap?
Abpro was worth $2.41M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ABPO's P/E ratio?
Abpro lost money over fiscal 2025 (diluted EPS -$1.30), so it has no meaningful P/E ratio.
Does Abpro pay a dividend?
No. Abpro has not paid a cash dividend over the last twelve months.
How has ABPO stock performed over the past year?
Including dividends, ABPO returned -92.8% over the past year, against +16.6% for the S&P 500.
Who are Abpro's competitors?
Companies most similar to Abpro by business, industry and size include ATYR, CMPX, AIM, ARTV, ZIVO.
See a number that looks wrong?